Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01722669 · ClinicalTrials.gov registry record · Early Phase 1
Quercetin PK/PD Study in Healthy Adults and Patients With Hypercoagulable States
A Early Phase 1 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 38
- Enrollment target
NCT01722669: Completed Early Phase 1 study, sponsored by Beth Israel Deaconess Medical Center.
NCT01722669 is a Early Phase 1 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 38 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (28% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01722669, a Early Phase 1 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
The goal of this study is to evaluate how much quercetin or isoquercetin is absorbed after a single dose and evaluate for pharmacokinetic inhibition of protein disulfide isomerase. Pharmacodynamic studies will also be performed in an additional cohort of 10 patients with evidence of antiphospholipid antibodies
Primary Outcome
AUC 0-24 hours of measured plasma quercetin aglycone for Arms A1, B1, A2, B2, C Collected at timepoints: baseline and 1, 2, 4, 6, 8, and 24 hours after dose. PK and PDI samples were not measured for Arm D (anti-phospholipid antibody cohort)
Interventions
- DRUG isoquercetin or quercetin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2012-05 |
| Est. Completion | 2019-12 |
| Phase | Early Phase 1 |
What the finished NCT01722669 record still lists
NCT01722669 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (28% lower).
The record links to 0 conditions, and to 1 intervention - of which isoquercetin or quercetin is the first listed.
NCT01722669 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01722669 about?
NCT01722669 is a clinical study titled "Quercetin PK/PD Study in Healthy Adults and Patients With Hypercoagulable States". The goal of this study is to evaluate how much quercetin or isoquercetin is absorbed after a single dose and evaluate for pharmacokinetic inhibition of protein disulfide isomerase. Pharmacodynamic studies will also be performed in an additional cohort of 10 patients with evidence of antiphospholipid...
What is the current status of trial NCT01722669?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 38 participants. The study started on 2012-05. Estimated completion is 2019-12.
What interventions are being tested in trial NCT01722669?
The interventions under investigation include: isoquercetin or quercetin (DRUG).
Who is sponsoring clinical trial NCT01722669?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01722669's enrollment target sits among peer trials
38 699th of 2000 higher than 1,299 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia